Biogen To Nearly Double Japan Staff As Drug Pipeline Expands
This article was originally published in PharmAsia News
Executive Summary
Biogen Idec said it would increase its sales staff by half instead of seeking a partner in Japan to sell its multiple sclerosis and hemophilia drugs set to enter the market by year's end.